Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations

Abstract Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors are standard therapeutic agents for non‐small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations re...

Full description

Bibliographic Details
Main Authors: Mio Kanbe, Noriaki Sunaga, Kenichiro Hara, Hiiru Sawada, Ikuo Wakamatsu, Kentaro Hara, Sohei Muto, Yuri Sawada, Hiroaki Masubuchi, Mari Sato, Yosuke Miura, Hiroaki Tsurumaki, Masakiyo Yatomi, Reiko Sakurai, Yasuhiko Koga, Yoichi Ohtaki, Toshiteru Nagashima, Naoko Okano, Nobuteru Kubo, Toshitaka Maeno, Takeshi Hisada
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Thoracic Cancer
Subjects:
afatinib
epidermal growth factor receptor
progression‐free survival
Online Access:https://doi.org/10.1111/1759-7714.14678

Internet

https://doi.org/10.1111/1759-7714.14678

Similar Items